Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB094 in Adults With Parkinson's Disease
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 82
- Registration Number
- NCT03976349
- Locations
- 🇪🇸
Laboratorios de Investigación Biocruces 3., Hospital de Cruces, Barakaldo, Bizkaia, Spain
🇺🇸Northwestern University PD and Movement Disorders Center, Chicago, Illinois, United States
🇺🇸The Cleveland Clinic Foundation, Cleveland, Ohio, United States
A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 142
- Registration Number
- NCT03958877
- Locations
- 🇧🇪
Clinique CHC MontLégia, Liege, Wallonia, Belgium
🇭🇷Clinical Hospital Center 'Sestre Milosrdnice', Zagreb, Croatia
🇩🇪St. Josef-Hospital Universitaetsklinikum, Bochum, Nordrhein Westfalen, Germany
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis
- First Posted Date
- 2019-05-10
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 49
- Registration Number
- NCT03945279
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸University of California San Diego Medical Center, San Diego, California, United States
🇺🇸University of South Florida, Tampa, Florida, United States
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of BIIB091, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Healthy Adult Participants
- First Posted Date
- 2019-05-09
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 64
- Registration Number
- NCT03943056
- Locations
- 🇺🇸
Research Site, Dallas, Texas, United States
Feasibility of the Multiple Sclerosis Performance Test in Participants With Multiple Sclerosis
- Conditions
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-01-30
- Lead Sponsor
- Biogen
- Target Recruit Count
- 3073
- Registration Number
- NCT03926637
- Locations
- 🇬🇧
Research Site, Oxford, United Kingdom
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
- Conditions
- Interventions
- First Posted Date
- 2019-03-12
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- Biogen
- Target Recruit Count
- 11
- Registration Number
- NCT03870763
- Locations
- 🇹🇷
Research Site, Samsun, Turkey
A Study to Evaluate SAGE-217 in Adult Participants With Major Depressive Disorder (MDD)
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1515
- Registration Number
- NCT03864614
- Locations
- 🇺🇸
Sage Investigational Site, Bellevue, Washington, United States
🇺🇸Sage Investigational site, Cincinnati, Ohio, United States
A Study to Evaluate the Safety, Tolerability, and Efficacy of SAGE-217 Compared to Placebo in Adult Participants With Comorbid Major Depressive Disorder (MDD) and Insomnia
- Conditions
- Interventions
- First Posted Date
- 2018-12-11
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Biogen
- Target Recruit Count
- 87
- Registration Number
- NCT03771664
- Locations
- 🇺🇸
Sage Investigational Site, Austin, Texas, United States
A Study to Evaluate Safety, Tolerability, and Distribution of a Microdose of Radiolabeled BIIB067 (99mTc-MAG3-BIIB067) Co-administered With BIIB067 (Tofersen) to Healthy Adults
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT03764488
- Locations
- 🇺🇸
Research Site, New York, New York, United States
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
- Conditions
- Interventions
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- Biogen
- Target Recruit Count
- 195
- Registration Number
- NCT03745820
- Locations
- 🇺🇸
Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Augusta University, Augusta, Georgia, United States
🇺🇸Hassman Research Institute, Berlin, New Jersey, United States